[go: up one dir, main page]

WO2003048134A1 - Compose de triazole et son utilisation therapeutique - Google Patents

Compose de triazole et son utilisation therapeutique Download PDF

Info

Publication number
WO2003048134A1
WO2003048134A1 PCT/JP2002/012735 JP0212735W WO03048134A1 WO 2003048134 A1 WO2003048134 A1 WO 2003048134A1 JP 0212735 W JP0212735 W JP 0212735W WO 03048134 A1 WO03048134 A1 WO 03048134A1
Authority
WO
WIPO (PCT)
Prior art keywords
haloalkyl
alkyl
triazole compound
halogeno
nitro
Prior art date
Application number
PCT/JP2002/012735
Other languages
English (en)
Japanese (ja)
Inventor
Yuki Kitao
Hiroshi Kawakami
Akira Matsuo
Original Assignee
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc. filed Critical Japan Tobacco Inc.
Priority to AU2002354410A priority Critical patent/AU2002354410A1/en
Priority to JP2003549326A priority patent/JPWO2003048134A1/ja
Publication of WO2003048134A1 publication Critical patent/WO2003048134A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un inhibiteur du cotransporteur sodium-phosphate, contenant un composé de triazole représenté par la formule générale (I), où : R1, R2 et R3 sont identiques ou différents et représentent chacun hydrogène, haloalkyle C1-6, halogéno, nitro, amino, cyano, alkyle C1-7, alcoxy C1-6, etc. ; R4 représente haloalkyle C1-6, alkyle C1-7, etc. ; R5, R6, R7 et R8 sont identiques ou différents et représentent chacun hydrogène, halogéno, haloalkyle C1-6, alkyle C1-7, alcoxy C1-6, ou nitro ; et l'anneau A représente aryle ou un groupe hétérocyclique aromatique. L'invention a également trait à un promédicament et à un sel pharmaceutiquement acceptable dudit inhibiteur. Ledit inhibiteur, qui présente une activité inhibitrice du cotransporteur sodium-phosphate, sert d'agent thérapeutique dans le traitement de l'hyperphosphatémie.
PCT/JP2002/012735 2001-12-05 2002-12-04 Compose de triazole et son utilisation therapeutique WO2003048134A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002354410A AU2002354410A1 (en) 2001-12-05 2002-12-04 Triazole compound and medicinal use thereof
JP2003549326A JPWO2003048134A1 (ja) 2001-12-05 2002-12-04 トリアゾール化合物及びその医薬用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001371687 2001-12-05
JP2001/371687 2001-12-05

Publications (1)

Publication Number Publication Date
WO2003048134A1 true WO2003048134A1 (fr) 2003-06-12

Family

ID=19180699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012735 WO2003048134A1 (fr) 2001-12-05 2002-12-04 Compose de triazole et son utilisation therapeutique

Country Status (3)

Country Link
JP (1) JPWO2003048134A1 (fr)
AU (1) AU2002354410A1 (fr)
WO (1) WO2003048134A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862060A1 (fr) * 2003-11-06 2005-05-13 Galderma Res & Dev Procede de synthese en phase solide de composes de types sulfures de diaryle.
WO2007015809A3 (fr) * 2005-07-22 2007-03-29 Merck & Co Inc Inhibiteurs de la transcriptase inverse du vih
WO2011136269A1 (fr) 2010-04-28 2011-11-03 アステラス製薬株式会社 Composé de tétrahydrobenzothiophène
WO2013062065A1 (fr) 2011-10-27 2013-05-02 アステラス製薬株式会社 Dérivé de n-thiényl benzamide substitué avec un aminoalkyle
WO2014029983A1 (fr) 2012-08-21 2014-02-27 Ardelyx, Inc. Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal
US8722695B2 (en) 2009-12-11 2014-05-13 Autifony Therapeutics Limited Imidazolidinedione derivatives
US9133175B2 (en) 2010-12-06 2015-09-15 Autifony Therapeutics Limited Compounds
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
US9198923B2 (en) 2009-01-26 2015-12-01 Opko Ireland Global Holdings, Ltd. Phosphate management with small molecules
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
US9669030B2 (en) 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
WO2018129552A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés utiles pour le traitement de troubles du tractus digestif
WO2018129557A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibiteurs d'antiport à médiation par nhe
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
EP3351248A1 (fr) 2008-12-31 2018-07-25 Ardelyx, Inc. Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal
RU2662817C2 (ru) * 2013-04-24 2018-07-31 Дайити Санкио Компани, Лимитед Соединение дикарбоновой кислоты
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2023219127A1 (fr) * 2022-05-11 2023-11-16 中外製薬株式会社 Composition pharmaceutique pour le traitement ou la prévention d'une maladie kystique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769411A (en) * 1968-09-04 1973-10-30 Rohm & Haas Fungicidal 1,2,4-4h-triazole derivatives
US4372953A (en) * 1980-02-29 1983-02-08 Otsuka Pharmaceutical Company, Limited Tetrazole derivatives, and anti-ulcer composition containing the same
US4820625A (en) * 1986-09-19 1989-04-11 Fuji Photo Film Co., Ltd. Direct positive silver halide photographic material
WO1999002503A1 (fr) * 1997-07-07 1999-01-21 Basf Aktiengesellschaft Composes de triazole et leur utilisation comme ligands de la dopamine d¿3?

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769411A (en) * 1968-09-04 1973-10-30 Rohm & Haas Fungicidal 1,2,4-4h-triazole derivatives
US4372953A (en) * 1980-02-29 1983-02-08 Otsuka Pharmaceutical Company, Limited Tetrazole derivatives, and anti-ulcer composition containing the same
US4820625A (en) * 1986-09-19 1989-04-11 Fuji Photo Film Co., Ltd. Direct positive silver halide photographic material
WO1999002503A1 (fr) * 1997-07-07 1999-01-21 Basf Aktiengesellschaft Composes de triazole et leur utilisation comme ligands de la dopamine d¿3?

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047237A1 (fr) * 2003-11-06 2005-05-26 Galderma Research & Development, S.N.C. Procede de synthese en phase solide de composes de types sulfures de diaryle
FR2862060A1 (fr) * 2003-11-06 2005-05-13 Galderma Res & Dev Procede de synthese en phase solide de composes de types sulfures de diaryle.
WO2007015809A3 (fr) * 2005-07-22 2007-03-29 Merck & Co Inc Inhibiteurs de la transcriptase inverse du vih
US7807684B2 (en) 2005-07-22 2010-10-05 Merck Sharp & Dohme Corp. HIV reverse transcriptase inhibitors
EP3939964A1 (fr) 2008-12-31 2022-01-19 Ardelyx, Inc. Combinaisons d'inhibition d'un antiport a mediation par nhe dans le traitement de troubles associes a une retention de fluide ou a une surcharge de sel et de troubles du tractus gastro-intestinal
EP3351248A1 (fr) 2008-12-31 2018-07-25 Ardelyx, Inc. Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal
US9198923B2 (en) 2009-01-26 2015-12-01 Opko Ireland Global Holdings, Ltd. Phosphate management with small molecules
US10058551B2 (en) 2009-12-11 2018-08-28 Autifony Therapeutics Limited Imidazolidinedione derivatives
US9216967B2 (en) 2009-12-11 2015-12-22 Autifony Therapeutics Limited Imidazolidinedione derivatives
US9849131B2 (en) 2009-12-11 2017-12-26 Autifony Therapeutics Limited Imidazolidinedione derivatives
US10632118B2 (en) 2009-12-11 2020-04-28 Autifony Therapeutics Limited Imidazolidinedione derivatives
US8722695B2 (en) 2009-12-11 2014-05-13 Autifony Therapeutics Limited Imidazolidinedione derivatives
WO2011136269A1 (fr) 2010-04-28 2011-11-03 アステラス製薬株式会社 Composé de tétrahydrobenzothiophène
JP5617919B2 (ja) * 2010-04-28 2014-11-05 アステラス製薬株式会社 テトラヒドロベンゾチオフェン化合物
US8729068B2 (en) 2010-04-28 2014-05-20 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
KR20130073908A (ko) 2010-04-28 2013-07-03 아스텔라스세이야쿠 가부시키가이샤 테트라하이드로벤조티오펜 화합물
US9284295B2 (en) 2010-04-28 2016-03-15 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
CN102869656A (zh) * 2010-04-28 2013-01-09 安斯泰来制药株式会社 四氢苯并噻吩化合物
EA022521B1 (ru) * 2010-04-28 2016-01-29 Астеллас Фарма Инк. Соединения тетрагидробензотиофена, фармацевтическая композиция на их основе, их применение и способ лечения гиперфосфатемии
US10555945B2 (en) 2010-12-06 2020-02-11 Autifony Therapeutics Limited Compounds
US10265316B2 (en) 2010-12-06 2019-04-23 Autifony Therapeuctics Limited Hydantoin derivatives useful as Kv3 inhibitors
US9346790B2 (en) 2010-12-06 2016-05-24 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US9422272B2 (en) 2010-12-06 2016-08-23 Autifony Therapeutics Limited Compounds
US10835534B2 (en) 2010-12-06 2020-11-17 Autifony Therapeutics Limited Compounds
US10098881B2 (en) 2010-12-06 2018-10-16 Autifony Therapeutics Limited Compounds
US9833452B2 (en) 2010-12-06 2017-12-05 Autifony Therapeutics Limited Compounds
US9133175B2 (en) 2010-12-06 2015-09-15 Autifony Therapeutics Limited Compounds
US11583527B2 (en) 2010-12-06 2023-02-21 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US11541052B2 (en) 2010-12-06 2023-01-03 Autifony Therapeutics Limited Compounds
US11197859B2 (en) 2010-12-06 2021-12-14 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
US9062032B2 (en) 2011-10-27 2015-06-23 Astellas Pharma Inc. Aminoalkyl-substituted N-thienylbenzamide derivative
WO2013062065A1 (fr) 2011-10-27 2013-05-02 アステラス製薬株式会社 Dérivé de n-thiényl benzamide substitué avec un aminoalkyle
JPWO2013062065A1 (ja) * 2011-10-27 2015-04-02 アステラス製薬株式会社 アミノアルキル置換ｎ−チエニルベンズアミド誘導体
KR20140096322A (ko) 2011-10-27 2014-08-05 아스텔라스세이야쿠 가부시키가이샤 아미노 알킬 치환 n-티에닐벤즈아미드 유도체
US9669030B2 (en) 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
US10160730B2 (en) 2012-05-22 2018-12-25 Autifony Therapeutics Limited Triazoles as KV3 inhibitors
US11180461B2 (en) 2012-05-22 2021-11-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
US10611735B2 (en) 2012-05-22 2020-04-07 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (fr) 2012-08-21 2014-02-27 Ardelyx, Inc. Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
US10940146B2 (en) 2013-04-12 2021-03-09 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
RU2662817C2 (ru) * 2013-04-24 2018-07-31 Дайити Санкио Компани, Лимитед Соединение дикарбоновой кислоты
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
US11242337B2 (en) 2017-01-09 2022-02-08 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2018129557A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibiteurs d'antiport à médiation par nhe
WO2018129552A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés utiles pour le traitement de troubles du tractus digestif
US12281103B2 (en) 2017-01-09 2025-04-22 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2023219127A1 (fr) * 2022-05-11 2023-11-16 中外製薬株式会社 Composition pharmaceutique pour le traitement ou la prévention d'une maladie kystique

Also Published As

Publication number Publication date
JPWO2003048134A1 (ja) 2005-04-14
AU2002354410A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003048134A1 (fr) Compose de triazole et son utilisation therapeutique
TW200500362A (en) 5-membered heteroaromatic ring compound and pharmaceutical use thereof
EP1156045A4 (fr) Derives d'amides et compositions de medicaments
WO2001009103A3 (fr) Agents antiproliferatifs imidazole
CA2534024A1 (fr) Nouveaux composes possedant une activite inhibitrice dirigee contre le transporteur dependant du sodium
WO2005097129A3 (fr) Compose de 6-azaindole
EP1396493A4 (fr) Composes heterocycliques
WO2002057252A3 (fr) Inhibiteurs sulfonamides heterocycliques de la production de beta-amyloide
WO2007071632A3 (fr) Derives de pyridinyl-quinazoline et leur utilisation medicale
GEP20063890B (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
EA200300695A1 (ru) Ингибитор высвобождения воспалительного цитокина
TNSN03045A1 (fr) Quinazolines as mmp-13 inhibitors
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
WO2002083111A3 (fr) Substance d'ouverture du canal k activee par le calcium a grande conductance
NZ512184A (en) Aromatic heterocycle compounds having HIV integrase inhibiting activities
WO2005012269A8 (fr) Nouveau compose azole
WO2004055005A8 (fr) Nouveaux composes possedant un effet d'inhibition selective de la gsk3
WO2005092858A3 (fr) Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
PT892793E (pt) Derivados 2-cianoiminoimidazolo inibidores da pde iv
CA2384354A1 (fr) Derives de pyrimidine et herbicides les contenant
WO2005095395A3 (fr) Derives de tetrahydronaphtyridine et procede d’elaboration desdits derives
EP1243268A4 (fr) Composition medicinale
CA2383583A1 (fr) Derive de benzopyran
WO2001003685A3 (fr) Nouveaux promedicaments pour amidines antimicrobiennes
WO2002062767A1 (fr) Nouveaux derives de quinazoline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AU AZ BA BB BR BY BZ CA CN CO CR CU DM DZ EC GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NO NZ OM PH PL RO RU SC SG TJ TM TN TT UA US UZ VC VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003549326

Country of ref document: JP

122 Ep: pct application non-entry in european phase